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Clinical Studies
Altered Orcadian Blood Pressure Rhythm in
Patients with Cushing's Syndrome
YUTAKA IMAI, KEISHI ABE, SHUICHI SASAKI, NAOYOSHI MLNAMI,
MLNORU NLHEI, MASANORI MUNAKATA, OSAMU MURAKAMI,
KATSUHIKO MATSUE, HIROSHI SEKINO, YUKIO MIURA,
AND KAORU YOSHINAGA
SUMMARY The circadian blood pressure rhythm was compared in patients with Cushing's syndrome,
essential hypertension, and primary aldosteronism. In patients with essential hypertension or primary
aldosteronism, a dear nocturnal fall hi systolic and diastolk blood pressure and heart rate was observed.
This fall was seen in untreated subjects as well as hi patients receiving combined treatment with a calcium
antagonist, diuretic, converting enzyme inhibitor, a-blocker and 0-blocker, or sympatholytic drug. In
these groups, there was a positive correlation between heart rate and systolic or diastolic blood pressure.
On the other hand, hi patients with Cushing's syndrome, there was no nocturnal fall hi blood pressure but
in some patients a rise was observed. In all patients there was a nocturnal fall hi heart rate. Thus, there
was no significant correlation between heart rate and blood pressure hi these patients. Exogenous
glucocortkoid eliminated the normal nocturnal fall of blood pressure hi patients with chronic glomeru-
lonephritis or systemic lupus erythematosus. These results suggest that the changed circadian blood
pressure pattern hi patients with Cushing's syndrome is not due to antihypertensive treatment or to the
mineralocorticold excess accompanying this disease, but it is attributable to excess glucocorticoid or the
associated disturbance hi the adrenocorticotropic hormone-glucocorticoid system (or both). This conclu-
sion also implies that the normal circadian rhythm of blood pressure may be regulated at least in part by
the adrenocorticotropic hormone -glucocorticoid system. (Hypertension 12: 11-19, 1988)
KEY WORDS • Cushing's syndrome . • blood pressure • heart rate • circadian rhythm
blood pressure monitoring • essential hypertension • primary aldosteronism • cortisol
CIRCADIAN fluctuations of blood pressure(BP) have been postulated,1 and it has beenshown that BP reaches a nadir at approxi-
mately 0300, begins to rise again at 0500, and
reaches its highest level at about 0900. The latter
increase is said not to be associated with physical
activity.1 Several researchers have claimed that the
fluctuations observed in BP are related to daily
activities such as sleep and physical exertion2-5
rather than the presence of an independent BP
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rhythm related to time alone. An absence of any
sleep-related reductions in BP has been noted in
several disease states, such as malignant hyperten-
sion,6 pheochromocytoma,7 preeclampsia,8 and auto-
nomic failure,9 and this fact is frequently cited
against the hypothesis of a circadian BP rhythm that
is affected by physical activities and the length and
depth of sleep. Whatever the explanation, the most
conspicuous and consistent finding in all studies on
normal subjects and essential hypertensive patients
is a nocturnal fall in BP when subjects are asleep. In
the present study, we tentatively refer to it as the
circadian BP rhythm. Although the controlling mech-
anisms of circadian BP rhythm remain uncertain, it
would seem likely that several factors are contrib-
uting. These may include neurohumoral changes
acting through the sympathetic nervous system, the
adrenocorticotropic hormone (ACTH)-cortisol sys-
tem, the renin-angiotensin-aldosterone system, the
vasopressin system, and cardiovascular depressor
mechanisms. In the present study, we examined the
11
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TABLE 1.
Group
Characteristics of Patients in Each Group
Age (yr) Drug scoring
SBP (mm
Day
Hg)
Night
DBP
Day
(mm Hg)
Night
HR
Day
(bcats/min)
Night
1. EH, drug-free (n = 38) 40.8± 14.2 0
2. EH, with treatment (n = 32) 51.2+11.3 3.3 ± 1.5
3. EH, severe hypertension (n= 12) 48.5± 16.3 l.6±0.5
4. Pituitary Cushing (n= 11) 38.1 ± 15.9 1.9+1.5
5. Adrenal Cushing (n = 4) 43.8±4.0 1.3 =t 1.0
6. Ectopic ACTH (n= I) 41 6.0
7. PA(n=13) 40.9±10.6 0.7±0.9
141 ±2.3
127±3.0
162 ±2.0
147 ±4.8
168±7.9
163
144±3.9
127±2.5
118±3.3
143±3.1
146±5.6
168±12.8
167
126 ±9.9
88 ±2.4
85 ±2.2
1OO±3.5
92±4.2
95 ±8.0
99
93 ±2.2
78 ±2.6
78 ±2.4
90±3.4
90±4.6
99±5.3
100
85 ±3.6
70±1.3
66±1.6
74 ±2.3
81 ±2.9
73 ±5.0
102
73 ±2.2
57±l.O
60±1.7
63+1.5
67±2.6
58±5.4
102
63 ±2.0
Age and drug scoring values are means ± SD. Remaining values are means ± SEM. Drug scoring system has been shown elsewhere.11
SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; EH = essential hypertension; with treatment =
patients treated with antihypertensive drugs; Cushing = Cushing's syndrome; ectopic ACTH = ectopic ACTH-producing tumor; PA
= primary aldosteronism.
relationships between the circadian BP rhythm and
the disturbance of the pituitary-adrenal axis. BP
was monitored for 24 hours in patients with Cush-
ing's syndrome, as a model of the disturbed ACTH-
cortisol system. We also investigated the influence
of excess glucocorticoid on circadian BP rhythm.
The 24-hour BP was measured with a noninvasive
automatic monitoring device, which we have devel-
oped recently based on the volume oscillometric
technique, recording the BP indirectly at the
finger.10
Subjects and Methods
In the present study, we monitored 24-hour BP in
patients with Cushing's syndrome, primary aldoste-
ronism, or essential hypertension. The ages and
preexisting treatments in these subjects are summa-
rized in Table 1. In the first two groups, diagnosis
was made by clinical features and results of hor-
monal, radiological, and general biochemical tests.
The characteristics of patients with Cushing's syn-
drome and those with primary aldosteronism are
shown respectively in Tables 2 and 3. For diagnosis
of Cushing's syndrome, the 8-mg dexamethasone
suppression test as well as the single bedtime 1-mg
dexamethasone suppression test was performed. As
shown in Table 2, plasma cortisol was not sup-
pressed below 1 /xg/dl by dexamethasone in all
patients with Cushing's syndrome. To differentiate
the type of Cushing's syndrome, plasma ACTH was
measured. For screening of primary aldosteronism,
plasma renin activity and plasma aldosterone con-
centration were measured and stimulation tests for
renin release with furosemide were performed.
TABLE 2. Clinical Data in Patients with Cushing's Syndrome
Patient no.,
sex, age (yr)
1. F, 29
2. M, 26
3. F, 47
4. F, 44
5. M, 53
6. F, 59
7. M, 15
8. F, 36
9. M, 16
10. F, 60
11. F, 34
12. F, 46
13. M, 48
14. F, 42
15. F, 39
16. F, 41
Diagnosis
Pit A
Pit A
Pit A
Pit A
Pit A
Pit A
Pit A
Pit A
Pit A
Pit A
Pit A
RAA
RAA
LAA
RAA
Ectopic
Na
(mEq/L)
145
138
145
143
148
143
143
142
143
144
142
144
144
143
142
144
Plasma
K
(mEq/L)
4.5
4.0
4.0
3.9
2.4
3.2
3.9
4.2
3.4
2.8
4.2
3.0
3.8
3.6
3.7
3.5
ACTH
(pg/ml)
47.9
167.7
58.1
66.4
137.8
105.0
46.0
168.5
50.2
153.0
70.0
10.0
10.0
10.0
10.0
157.0
Cortisol
(MB/dl)
19.8
31.8
17.3
17.7
67.3
16.1
39.1
19.2
21.5
51.5
16.6
36.0
18.2
17.7
20.0
24.5
Plasma
cortisol
(Mg/dl)
Dexa,
1 mg
18.4
20.5
3.2
19.1
44.3
3.3
25.0
31.7
27.0
13.3
22.3
25.4
11.9
17.8
27.1
9.7
Dexa,
8mg
4.5
7.6
2.5
14.3
38.7
2.8
12.4
20.4
15.0
12.9
14.5
23.8
13.3
18.9
20.0
9.5
PRA
(ng Ang 1/
ml/6 hr)
4.2
2.4
8.1
5.7
4.4
8.0
7.1
—
6.5
10.4
—
29.9
5.1
2.0
3.7
—
PAC
(ng/dl)
0.2
4.4
7.8
7.5
9.9
10.2
8.3
—
9.0
13.9
—
6.8
8.5
0.2
5.7
—
Urinary excretion
NE
(Mg/day)
—
25.6
58.8
—
—
13.5
15.1
27.5
—
13.7
—
20.4
15.4
—
27.1
—
E
(Mg/day)
—
ND
7.7
—
—
1.6
0.2
ND
—
1.8
ND
1.3
—
ND
—
17-OHCS
(mg/day)
17.6
18.8
13.3
14.6
61.2
47.5
14.9
26.2
17.5
31.5
10.4
22.0
18.1
18.5
21.5
47.1
Dexa = dexamethasone; PRA = plasma renin activity; Ang I = angiotensin I; PAC =
norepinephrine; E = epinephrine; 17-OHCS = 17-hydroxycorticosteroid; R = right; L =
adrenal adenoma; ectopic = ectopic ACTH-producing tumor; ND = not detectable.
plasma aldosterone concentration; NE
left; Pit A = pituitary adenoma; AA
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TABLE 3. Clinical Data in Patients with Primary Aldosteronism
Patient no.,
sex, age (yr)
1. F, 31
2. F, 48
3. M, 40
4. F, 46
5. F, 34
6. F, 45
7. F, 28
8. F, 31
9. F, 38
10. F, 44
11. M, 59
12. M, 60
13. F, 28
Diagnosis
LAA
RAA
RAA
LAA
LAA
LAA
RAA
RAA
RAA
LAA
LAA
LAA
RAA
Plasma Na
(mEq/L)
142
146
144
146
144
142
147
144
142
141
142
147
147
Plasma K
(mEq/L)
3.4
3.3
2.9
3.1
3.1
3.4
2.4
3.1
3.1
3.4
3.2
2.7
2.5
PRA
(ng Ang I/ml/dl)
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
PAC
(ng/dl)
42.9
27.7
18.0
18.5
23.0
29.1
33.5
17.9
49.0
23.0
34.1
19.0
34.1
PRA = plasma renin activity; Ang 1 = angiotensin I; PAC = plasma aldostcrone concentration; LAA = left
adrenal adenoma; RAA = right adrenal adenoma.
[131I]Iodomethyl-19-norcholesterol scintigraphy (with
and without dexamethasone treatment) and com-
puted tomography (CT) were performed. The adre-
nal adenoma was confirmed by the CT scanner.
Pituitary microadenoma was also confirmed by the
CT scanner in the majority of patients with pituitary
Cushing's syndrome. The pituitary or adrenocor-
tical adenomas were confirmed later by operation.
One patient with an ectopic ACTH-producing tumor
(i.e., a carcinoid in the transverse colon and its
metastatic tumors) was included in the Cushing's
syndrome group. In patients with essential hyper-
tension, routine screening tests were performed to
rule out the possibility of secondary hypertension.
In all, 29 monitoring sessions were performed in
16 patients with Cushing's syndrome. Since several
patients with Cushing's syndrome had a diastolic
BP (DBP) above 120 mm Hg, a study in the absence
of antihypertensive medication was not always pos-
sible. In six of the 29 monitoring sessions, patients
were not treated with antihypertensive drugs. In the
remaining monitoring sessions several kinds of anti-
hypertensive drugs were used. The circadian BP
rhythm in patients with several types of Cushing's
syndrome (Groups 4, 5, and 6), including those
treated with antihypertensive drugs and without
benzodiazepine, was compared with that in subjects
with untreated Cushing's syndrome, untreated essen-
tial hypertension (Group 1), or essential hyperten-
sion treated with antihypertensive drugs (Group 2).
In most patients with Cushing's syndrome some kind
of calcium-antagonistic vasodilator was used as a part
of the antihypertensive drug regimen. Therefore, the
effects of a calcium antagonist in combination with a
diuretic, converting enzyme inhibitor, a-blocker and
/3-blocker, or sympatholytic drug on the circadian BP
rhythm were examined in patients with essential hyper-
tension (Group 2). As shown in Results, the BP level
in patients with Cushing's syndrome seems higher
when compared with that of essential hypertensive
patients, whether treated with combined antihyper-
tensive drugs or not. Therefore, we gathered essential
hypertensive patients who had undergone at least
calcium antagonist treatment and whose averaged
daytime systolic blood pressure (SBP) was more than
155 mm Hg (Group 3) and compared their circadian
BP rhythm with that of the patients with Cushing's
syndrome. The quality and quantity of antihyperten-
sive drugs were expressed collectively as a drug
score. The dose of a drug that effectively treats mild
hypertension was arbitrarily assigned a value of 1
point. This point system has been reported else-
where.11
In the present study, the quality and quantity of
sleep were also critical points in evaluating the
nocturnal change in BP. Patients who complained
of sleep disturbance on the day of BP monitoring
were not included in the study. In two patients with
Cushing's syndrome, overnight monitoring of elec-
troencephalogram (EEG) as well as 24-hour BP
monitoring was performed. In five patients with
Cushing's syndrome, 24-hour BP monitoring was
performed twice, with and without nitrazepam treat-
ment (10 mg at 2030). In six patients with chronic
glomerulonephritis or systemic lupus erythemato-
sus, the effect of prednisolone (45.0 ± 19.7 [mean ±
SD] mg, once in the morning every day [0800] over
a week or more; 54.2 ± 22.0 days [mean ± SD]) on
circadian BP rhythm was examined. The dose of
prednisolone at which BP monitoring was done was
shown. The dose was not necessarily maintained at
the same level during the period of prednisolone
treatment.
All BP monitorings were performed in a ward
setting. Nearly all the subjects were allowed their
usual activities in the ward. However, one patient
with ectopic ACTH-producing tumor was confined
to bed throughout the day. Another with adrenal
Cushing's syndrome (Patient 14) was asked to keep
recumbent as much as possible during the BP
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monitoring session when an overnight EEG was
performed.
BP Monitoring
The device used in the present study (BP-100
system, ME Commercial, Tokyo, Japan) can auto-
matically monitor SBP and mean BP in the human
finger using the volume-oscillometric method. Cal-
culated DBP is also available. The theoretical basis
of this method and technical details of this instru-
ment have been described elsewhere.1213 Briefly,
the method is designed to measure BP by detecting
the local arterial volume pulsation using a photo-
electric plethysmograph that is placed just below
the occluding cuff. During a gradual increase or de-
crease in the cuff pressure, the photoplethysmo-
graphic pulsations characteristically change in ampli-
tude and the systolic end point and the point showing
the maximum amplitude can be clearly determined.
The cuff pressure values corresponding to the systolic
end point and the maximum amplitude are in good
agreement with SBP and mean BP in the arterial
segment concerned.12-13 Performance of this device
and its stability for long-term BP monitoring have
been reported elsewhere.10
In the present study, BP was monitored every 5
minutes for 24 hours. Patients had breakfast at
about 0730, lunch at about 1130, and an evening
meal at 1700. All lights were put out at 2100, and
patients were awakened at 0600 by morning calls.
Biochemical Methods
Duplicate measurement of plasma ACTH
(CEA-IRE-Sorin, Gif-sur-Yvette, France), corti-
sol (Eiken, Tokyo, Japan), and aldosterone con-
centrations (Dynabot, Tokyo, Japan) were made
using commercial radioimmunoassay kits. Plasma
renin activity was determined with a modification
of Haber's method.14 Urinary catecholamines were
measured by a sensitive fluorometric method.13
Analytical Methods
Time-trend charts were constructed for SBP,
DBP, and heart rate (HR) averaged every hour by
computer for each disease group. Averages of SBP,
DBP, and HR during waking hours (0600-2059)
were compared with nighttime values (2100-0559)
using one-way analysis of variance and Student's /
test. A linear regression analysis was done on the
BP and HR data.
Results
Orcadian Rhythm of BP and HR in Patients with
Essential Hypertension (Group 1)
Figure 1A is a typical time-trend chart of BP and
HR in a subject with untreated essential hyperten-
sion. As shown in Figure 2A, a clear nocturnal fall
in SBP, DBP, and HR and two daytime peaks, one
in the morning (0800-0859) and the other in the late
afternoon (1600-1859), were observed in untreated
II
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FIGURE 1. A typical time-trend chart for BP and HR
in a subject with untreated essential hypertension (A),
ectopic ACTH-producing tumor (B), and adrenal Cush-
ing's syndrome (C). The electroencephalographic sleep
pattern is also shown in C. REM = rapid eye movement.
patients with essential hypertension. The changes
in BP were well correlated with those in HR (SBP:
r = 0.97, p < 0.01; DBP: r = 0.94, p < 0.01). BP
and HR gradually fell during the evening, reached a
nadir between 0100 and 0159, and then began to rise
again gradually.
Essential hypertensive patients who were treated
with combined antihypertensive drugs (Group 2;
Figure 2B) or whose averaged daytime SBP was
more than 155 mm Hg (Group 3; Figure 2C) dem-
onstrated almost similar circadian rhythm of BP and
HR to that in untreated subjects with essential
hypertension (Group 1; Figure 2A). In the former
two groups the changes in BP were correlated with
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FIGURE 2. Circadian rhythm ofSBP, DBP, and HR in 38 untreated subjects with essential hypertension
(A), in 32 essential hypertensive patients treated with combined antihypertensive drugs (B), and in 12
essential hypertensive patients whose averaged daytime SBP was more than 155 mm Hg (C).
those of HR (Group 2: SBP, r = 0.84, p < 0.01;
DBP, r = 0.80, p < 0.01; Group 3: SBP, r = 0.94,
p < 0.01; DBP, r = 0.88, p < 0.01).
Circadian Rhythm of BP and HR in
Patients with Cushing's Syndrome
Figure 3A demonstrates the circadian rhythm of
BP and HR in six untreated subjects with Cushing's
syndrome (Patients 6, 9-13). The circadian rhythm
of BP and HR in patients with pituitary Cushing's
syndrome (Group 4; 14 measurements in 11 patients)
and adrenal Cushing's syndrome (Group 5; 4 mea-
surements in 4 patients) is also demonstrated in
Figures 3B and C, respectively. In the patients with
pituitary Cushing's syndrome, multiple measure-
ments in a single patient were averaged, and then
these average values were used for the group anal-
ysis. Figure IB is an actual time-trend chart for BP
and HR in a patient with an ectopic ACTH-
producing tumor (Patient 16). As shown in these
figures, BP gradually rose between midnight and
early morning, reaching a peak just before or after
awakening of the patients with Cushing's syndrome
of different pathogenesis. Although the patterns of
circadian BP rhythm in Cushing's syndrome were
very different from those in subjects with treated or
untreated essential hypertension, the circadian HR
rhythm in the former was essentially the same as
that in the latter.
Although in many patients with Cushing's syn-
drome 24-hour BP monitoring was performed under
antihypertensive treatment (see Table 1), the pres-
ent results demonstrated that the treatment did not
affect the circadian BP rhythm in patients with
Cushing's syndrome (Figure 3A vs Figures 3B and
3C). A linear regression analysis demonstrated that
there was no correlation between BP and HR in
subjects with untreated Cushing's syndrome (SBP:
r = -0.04; DBP: r = 0.02), pituitary Cushing's
syndrome (SBP: r = -0.08; DBP: r = 0.18) or
adrenal Cushing's syndrome (SBP: r = -0.04,
DBP: r = -0.05); the latter two groups include
patients treated with antihypertensive drugs.
Figure 1C demonstrates a typical time-trend chart
for BP and HR with the sleep pattern of EEG in a
patient with adrenal Cushing's syndrome (Patient
14). As stated in the Methods section, the patients
with Cushing's syndrome slept undisturbed as usual
during the night of monitoring and were awakened
at about 0600 by a morning call. However, in two
patients with Cushing's syndrome (Patients 10 and
14), slow-wave sleep decreased and an increase in
Stage 2 sleep was observed instead. The latency
and sleep cycle of rapid eye movement (REM) sleep
was unchanged. As shown in Figure 4A, nitrazepam
did not affect the pattern of circadian BP rhythm in
Cushing's syndrome (Patients 6, 8, 13-15).
Effect of Exogenous Glucocorticoid on the
Circadian Rhythm of BP and HR in
Patients with Chronic Glomerulonephritis or
Systemic Lupus Erythematosus
As shown in Figure 4B, the pattern of circadian
BP rhythm in patients with chronic glomerulone-
phritis or systemic lupus erythematosus before the
treatment with prednisolone was essentially the
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FIGURE 3. Circadian rhythm ofSBP, DBP, and HR in six untreated subjects with Cushing's syndrome
(A), in II patients with pituitary Cushing's syndrome (B), in four patients with adrenal Cushing's
syndrome (C), and in 13 patients with primary aldosteronism (D).
same as in those with essential hypertension. Exog-
enous glucocorticoid eliminated the circadian BP
rhythm.
Circadian Rhythm of BP and HR in Patients with
Primary Aldosteronism
As shown in Figure 3D, the pattern of circadian
rhythm of BP and HR in patients with primary
aldosteronism was essentially the same as that in
patients with essential hypertension, but it was very
different from that in patients with Cushing's syn-
drome. The changes in BP were well correlated
with those of HR (SBP: r = 0.70, p < 0.01; DBP:
r = 0.78, p < 0.01).
Comparison Between Daytime and Nighttime
BPand HR
Table 1 shows the SBP, DBP, and HR averaged
separately for daytime and nighttime periods. In
untreated and treated subjects with essential hyper-
tension and primary aldosteronism, SBP and DBP
during the daytime were significantly higher than
those for the nighttime. In subjects with pituitary or
adrenal Cushing's syndrome, whether or not they
were treated with antihypertensive drugs, SBP and
DBP during the nighttime were not significantly
different from those during the daytime. Daytime
HR in all groups was significantly higher than
nighttime HR. The difference between daytime and
nighttime HR in patients treated with combined
antihypertensive drugs was significantly less than
that in the other groups.
Discussion
In the present study, we have demonstrated that
the circadian BP rhythm in patients with Cushing's
syndrome is very different from that in patients with
essential hypertension or primary aldosteronism.
The patients with Cushing's syndrome were some-
times treated with several kinds of antihypertensive
drugs because of their severe hypertension. How-
ever, the present study clearly demonstrates that a
calcium antagonist in combination with diuretic,
converting enzyme inhibitor, a-blocker and /3-
blocker, or sympatholytic drug did not affect the
pattern of circadian BP rhythm in patients with
Cushing's syndrome or essential hypertension. The
disturbance of normal circadian BP rhythm has
been reported in patients with malignant hyper-
tension.7 In the present study, hypertension in
Cushing's syndrome, especially in adrenal Cush-
ing's syndrome, was severe. Thus, the disturbance
of circadian rhythm of BP may have been the result
of severe hypertension. However, the circadian BP
rhythm in essential hypertensive patients whose
averaged daytime SBP was similar to that in patients1
with adrenal Cushing's syndrome remained undis-
turbed, suggesting that the BP level was not the sole
factor contributing to its disturbance. Almost all the
subjects examined in the present study had normal
physical activity and undisturbed sleep. Taken
together, these results suggest that the circadian BP
rhythm in patients with Cushing's syndrome (i.e.,
no nocturnal fall in BP and a peak BP level just
before or after waking) may be peculiar to this
syndrome. Furthermore, the present study demon-
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FIGURE 4. 77»e influence of drugs on the circadian rhythm ofSBP, DBP, and HR: that ofnitrazepam
in five patients with Cushing's syndrome (A) and that of prednisolone in six patients with chronic
glomerulonephritis or systemic lupus erythematosus (B).
strated that exogenous glucocorticoid abolished the
circadian BP rhythm in patients with chronic glo-
merulonephritis or systemic lupus erythematosus.
This finding indicates that excess glucocorticoid,
whether due to endogenous or exogenous glucocor-
ticoid, affects the circadian BP rhythm.
Glucocorticoids alter the distribution of body
fluid through their effect on vascular perme-
ability.16-18 Excess circulating glucocorticoid may
alter the fluid movement in response to a change in
position; body fluid may shift excessively from
extravascular to intravascular space when one shifts
from a supine to a recumbent position during sleep,
resulting in an increase in circulating volume, venous
return, and cardiac output. Such an increase may
raise the BP. This possibility is unlikely, since the
elevation of BP from midnight to early morning was
still observed in patients with Cushing's syndrome
who remained in a recumbent position throughout
the day.
In Cushing's syndrome, adrenal adenoma or the
excessive production of ACTH from pituitary micro-
adenoma causes excessive glucocorticoid secretion,
and the ordinary circadian rhythm, if any, of the
ACTH-cortisol system is disturbed.19-20 In the pres-
ent study we also observed that the plasma cortisol
level remained high throughout the day with little
rhythm in patients with Cushing's syndrome (data not
presented). Exogenous glucocorticoid also disturbs
the ordinary hypothalamic-pituitary periodicity. The
administration of glucocorticoid inhibits release of
corticotropin-releasing factor and thus suppresses both
the synthesis and release of ACTH. Such a distur-
bance of the hypothalamic-pituitary-adrenal axis may
affect sympathetic nervous functions. For example,
there is evidence that glucocorticoid modulates the
synthesis of the sympathetic neurotransmitter21 and
vascular response to catecholamine.22-24 Under nor-
mal circumstances steroid hormones are thought to
pass the blood-brain barrier,25 and it has been reported
that glucocorticoid acts centrally to increase sympa-
thetic nerve activity.26 It has also been shown that
adrenal catecholamine secretion is linked with ACTH
and cortisol release.27-M
Although the mechanism responsible for the noc-
turnal fall in BP is uncertain, withdrawal of sympa-
thetic tone may play a major role,29-31 and the
disturbance of the circadian rhythm of the ACTH-
cortisol system in Cushing's syndrome, whether
due to excess ACTH or cortisol, may disturb the
circadian rhythm of the sympathetic nervous sys-
tem, resulting in an altered circadian BP rhythm.
Many patients with Cushing's syndrome were
reported to show some altered slow-wave sleep,32
suggesting a change in the quality of sleep in Cush-
ing's syndrome. This was also confirmed in the
present study (i.e., decreased slow-wave sleep and
increased Stage 2 sleep). Changes in BP relating to
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sleep phases have been reported33; therefore, altered
sleep states in Cushing's syndrome may affect the
BP level at night. The elevation of BP during REM
sleep is well established.34 In the present study,
however, we found that the latency and sleep cycle
of REM sleep was undisturbed. It is not yet known
how increased time spent in Stage 2 sleep affects the
BP level. In the present study, we also found that
nitrazepam did not affect the BP pattern during
night sleep in patients with Cushing's syndrome.
Nitrazepam increases the time spent in Stage 2
sleep and decreases the time spent in REM sleep.35
Therefore, it is difficult to conclude that the change
in time spent in Stage 2 sleep or REM sleep (or
both) alone affects the nocturnal levels of BP in
Cushing's syndrome. However, it is possible that
the sleep state and the nocturnal behavior of BP,
linking with each other, were affected by a common
factor in Cushing's syndrome of a differential patho-
genesis.
Mineralocorticoid effects of excess glucocorti-
coid36 or excess production of aldosterone or
deoxycorticosterone37-38 in Cushing's syndrome do
not appear to explain the altered circadian BP
rhythm, since the pattern of BP changes in patients
with primary aldosteronism was substantially the
same as that in patients with essential hypertension.
The circadian BP rhythm in patients with primary
aldosteronism observed in the present study was
very different from that reported by Tanaka et al.39
These earlier workers reported that BP reached its
peak level around 20 to 24 hours. The reason for
this difference is not clear.
The present results have demonstrated that the
circadian BP rhythm is well correlated with that of
HR in patients with essential hypertension or pri-
mary aldosteronism. The nocturnal fall of HR was
retained in patients with Cushing's syndrome, but
that of BP was absent. Sleep bradycardia is due to
increased parasympathetic activity but not to a
decrease in sympathetic tone.40-41 This effect sug-
gests that the circadian rhythm of parasympathetic
tone remains unchanged in patients with Cushing's
syndrome; therefore, it is unlikely that the parasym-
pathetic nervous system contributes to the noctur-
nal fall in BP.
The disturbance of the normal circadian BP
rhythm has been reported in several pathophysiolog-
ical conditions, such as pheochromocytoma,6*
malignant hypertension,7 preeclampsia,8 and auto-
nomic failure.9 The present results have demon-
strated that the circadian BP rhythm is also dis-
turbed in patients with Cushing's syndrome. The
available evidence suggests that physical activity is
not of fundamental importance in determining the
daily variations in BP that have been described.
Although we cannot infer the existence of an inher-
ent circadian BP rhythm from the results of the
*Recently we reported that ordinary circadian rhythm of BP was
observed in patients with pheochromocytoma.42
present study, it may be hypothesized that the
circadian variation of BP is mediated at least in part
by the hypothalamic-pituitary-adrenal axis through
its action on the autonomic nervous system.
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